FDA-Inspected Site

Jubilant Cadista Pharmaceuticals, Inc.

14 FDA inspections are on record for Jubilant Cadista Pharmaceuticals, Inc. in Salisbury, United States.

483· Form 483 issued

Salisbury, United States · Last updated July 9, 2026

Overview

  • 14 FDA inspections are on record.
  • 6 inspections produced a Form 483.
  • The most recent recorded inspection date is 2025-01-15.

At a glance

Inspections

14

Form 483s

6

EIRs

0

Last outcome

Form 483

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
8 Jan 2025 – 15 Jan 2025Human Drugs483View 483 →
24 Feb 2020 – 28 Feb 2020Human Drugs483View 483 →
26 Apr 2018 – 4 May 2018Human DrugsClean
7 Mar 2017 – 8 Mar 2017Human DrugsClean
3 Aug 2015 – 7 Aug 2015Human Drugs483View 483 →
8 Jul 2014Human DrugsClean
22 Jul 2013 – 1 Aug 2013Human DrugsClean
5 Apr 2012Not recorded483View 483 →
23 Mar 2011Not recorded483View 483 →
29 Oct 2009Not recorded483View 483 →
10 Aug 2007Not recordedClean
20 May 2005Not recordedClean

Observations on record

Form 483 observations cited at this site, most recent first.

15 Jan 2025
21 CFR 211.110(d)

Rejected in-process materials not quarantined

Cited by Pushpa S Jayasekara

15 Jan 2025
21 CFR 211.180(c)

Records not made readily available to FDA

Cited by Pushpa S Jayasekara

15 Jan 2025
21 CFR 211.186(a)

Signature and checking of records -- 2 persons

Cited by Pushpa S Jayasekara

15 Jan 2025
21 CFR 211.188(b)(11)

Identification of Persons Performing Significant Steps

Cited by Pushpa S Jayasekara

15 Jan 2025
FDCA 582(b)(4)

Systems in place to comply with verifciation requirements

Cited by Pushpa S Jayasekara

Investigators

FDA investigators tied to this site in the record.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations3x
21 CFR 211.113(a)Cited across public-safe Form 483 observations2x
21 CFR 211.160(b)Cited across public-safe Form 483 observations2x
21 CFR 211.198(a)Cited across public-safe Form 483 observations2x
21 CFR 211.25(a)Cited across public-safe Form 483 observations2x
21 CFR 211.67(a)Cited across public-safe Form 483 observations2x
21 CFR 514.80(b)(1)Cited across public-safe Form 483 observations2x
21 CFR 211.100(b)Cited across public-safe Form 483 observations1x
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.110(b)Cited across public-safe Form 483 observations1x
21 CFR 211.110(d)Cited across public-safe Form 483 observations1x
21 CFR 211.115(b)Cited across public-safe Form 483 observations1x
21 CFR 211.122(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(f)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.180(c)Cited across public-safe Form 483 observations1x
21 CFR 211.186(a)Cited across public-safe Form 483 observations1x
21 CFR 211.188Cited across public-safe Form 483 observations1x
21 CFR 211.188(b)(11)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)Cited across public-safe Form 483 observations1x
21 CFR 211.204Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.68(a)Cited across public-safe Form 483 observations1x
FDCA 582(b)(4)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind Jubilant Cadista Pharmaceuticals, Inc.'s 6 Form 483s

Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat